Erdheim-Chester Disease Masquerading as Multiple Myeloma: A Case Report with Molecular Insights
DOI:
https://doi.org/10.21276/apalm.3609Keywords:
Erdheim-Chester Disease, BRAF Mutation, Bone Lesions, PET-CTAbstract
Background: Erdheim-Chester disease is a rare, clonal histiocytic disorder characterized by the accumulation of lipid-laden histiocytes in various organs. Its clinical and radiological presentations are often nonspecific and can closely mimic malignancies such as multiple myeloma. This case is being reported due to its unusual presentation with multiple lytic bone lesions, which posed a significant diagnostic challenge and led to initial consideration of a hematologic malignancy. The report also highlights the importance of histopathological and molecular evaluation in reaching a definitive diagnosis and guiding therapy.
Case Presentation: A 64-year-old South Asian male presented with low back pain with itching for 6 months. Laboratory investigations revealed anemia and elevated inflammatory markers but no evidence of monoclonal gammopathy or abnormal plasma cell proliferation. Imaging studies showed multiple mixed lytic-sclerotic lesions involving both axial and appendicular skeleton, initially raising suspicion for multiple myeloma. A bone marrow biopsy and trucut biopsy from a lung lesion showed sheets of foamy histiocytes with interspersed lymphocytes and fibrosis. Immunohistochemistry revealed positivity for CD68 and CD163, suggesting a diagnosis of non-Langerhans cell histiocytosis. Based on these findings, a final diagnosis of Erdheim-Chester disease was established.
Conclusion: This case underscores the diagnostic complexities associated with Erdheim-Chester disease, particularly when it presents with destructive bone lesions resembling multiple myeloma. It emphasizes the critical role of tissue biopsy, immunohistochemistry, and molecular analysis in distinguishing this rare entity from more common differential diagnoses. Early recognition and accurate diagnosis are essential, as targeted therapies can lead to significant clinical improvement and alter the disease course.
References
1. Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol. 2012;24(1):53-59.
2. Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage–dendritic cell lineages. Blood. 2016;127(22):2672–2681.
3. Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2017.
4. Diamond EL, Dagna L, Hyman DM, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124(4):483–492.
5. Dagna L, et al. Clinical and radiological features of Erdheim-Chester disease: a review. Eur J Intern Med. 2012;23(6):602-607.
6. Haroche J, Cohen-Aubart F, Amoura Z. Erdheim-Chester disease. Blood. 2020;135(16):1311-1318.
7. Elbaz Younes I, Ellis A, Zhang X. Updates on Erdheim-Chester disease. Hum Pathol Rep. 2022;28:300636.
8. Goyal G, Heaney ML, Collin M, et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020;135(22):1929-1945.
9. Krishnan Y, Sainulabdin G, Krishnan VP, Thanseer NTK. Chronic recurrent multifocal osteomyelitis masquerading as multifocal bone Langerhans cell histiocytosis in children: A case series from a tertiary cancer center. Tumor Discovery. 2024;3(3):3102.
10. Abeykoon JP, Ravindran A, Rech KL, et al. Mimics of Erdheim-Chester disease. Br J Haematol. 2022;196(4):984-994.
11. Durham BH, Diamond EL, Abdel-Wahab O. Histiocytic neoplasms in the era of personalized genomic medicine. Curr Opin Hematol. 2016;23(4):416-25.
12. Goraro F, Papo M, Maniscalco V, Vaglio A, Haroche J. Erdheim–Chester disease: a rapidly evolving disease model. Leukemia. 2020;34(11):2840–2857.
13. Haroche J, Cohen-Aubart F, Amoura Z. Erdheim–Chester disease. Blood. 2020;135(16):1348–1353.
14. Shi X, Sun G, Li T, et al. Erdheim-Chester disease of multisystem involvement with delayed diagnosis: a case report and literature review. Exp Ther Med. 2024;27(4):159.
15. Hashmi SS, Guha-Thakurta N, Ketonen L, et al. Central nervous system and head and neck histiocytoses: a comprehensive review on the spectrum of imaging findings. Neurographics. 2016;6(2):114–122.
16. Benson JC, Vaubel R, Ebne BA, et al. Erdheim-Chester Disease. AJNR Am J Neuroradiol. 2023;44(5):505-510.
17. Yoon SO. Pathologic characteristics of histiocytic and dendritic cell neoplasms. Blood Res. 2024;59(1):18.
18. Mazor RD, Manevich-Mazor M, Shoenfeld Y. Erdheim-Chester Disease: a comprehensive review of the literature. Orphanet J Rare Dis. 2013;8:137.
19. McClain KL, Bigenwald C, Collin M, et al. Histiocytic disorders. Nat Rev Dis Primers. 2021;7(1):73.
20. Powell P, Vitug G, Castro-Silva F, Ray A. A rare case of CD1a-negative Langerhans cell histiocytosis of the central nervous system in a child. Clin Case Rep. 2017;5(10):1664-1667.
21. Gulyás A, Pinczés LI, Mátyus J, et al. Case report: Targeted treatment strategies for Erdheim-Chester disease. Front Oncol. 2024;14:1305518.
22. Haroche J, Amoura Z, Trad SG, et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum. 2006;54(10):3330-3336.
23. Arnaud L, Malek Z, Archambaud F, et al. Erdheim-Chester disease: a comprehensive review of the literature. Orphanet J Rare Dis. 2009;4:17.
24. Maksimovic M, Baskaran D, Vinnicombe S, et al. FDG PET/CT in Erdheim-Chester Disease: Imaging Patterns and Diagnostic Pitfalls. Clin Nucl Med. 2022;47(3):e191–e198.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 B Deepthi, N. Rukmangadha, Aruna K. Prayaga
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
